Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
o-Institut de Recherche pour le Developpement-malaria refers to the clinical research program and therapeutic regimens evaluated by the Institut de Recherche pour le Développement (IRD) for malaria prevention. Specifically, this designation encompasses the PACOME trial, a Phase 3 randomized controlled study conducted in Benin. The trial evaluated the efficacy and safety of daily cotrimoxazole prophylaxis (a combination of sulfamethoxazole and trimethoprim) compared to intermittent preventive treatment (IPTp) with mefloquine for the prevention of pregnancy-associated malaria in HIV-infected women. The research aimed to identify optimal prevention strategies for this high-risk population, as standard sulfadoxine-pyrimethamine IPTp is often contraindicated due to potential cross-reactivity with cotrimoxazole prophylaxis used for HIV management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on o-Institut de Recherche pour le Developpement-malaria.